Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ALGS | Aligos Therapeutics Inc

Index- P/E- EPS (ttm)-1.92 Insider Own33.83% Shs Outstand42.92M Perf Week-1.84%
Market Cap30.19M Forward P/E- EPS next Y-1.33 Insider Trans0.00% Shs Float26.74M Perf Month-14.65%
Income-82.25M PEG- EPS next Q-0.47 Inst Own48.66% Short Float / Ratio2.86% / 11.01 Perf Quarter-23.07%
Sales17.25M P/S1.75 EPS this Y18.67% Inst Trans-6.87% Short Interest0.77M Perf Half Y-28.17%
Book/sh1.60 P/B0.47 EPS next Y27.32% ROA-56.99% Target Price4.50 Perf Year-32.09%
Cash/sh2.25 P/C0.33 EPS next 5Y- ROE-79.62% 52W Range0.70 - 2.41 Perf YTD-21.61%
Dividend- P/FCF- EPS past 5Y-57.80% ROI-104.37% 52W High-69.00% Beta2.18
Dividend %- Quick Ratio3.46 Sales past 5Y54.76% Gross Margin80.20% 52W Low6.71% ATR0.05
Employees83 Current Ratio3.46 Sales Q/Q86.46% Oper. Margin-490.89% RSI (14)34.56 Volatility7.13% 5.71%
OptionableYes Debt/Eq0.18 EPS Q/Q6.90% Profit Margin-476.77% Rel Volume0.37 Prev Close0.73
ShortableYes LT Debt/Eq0.13 EarningsAug 03 AMC Payout- Avg Volume69.50K Price0.75
Recom2.00 SMA20-7.00% SMA50-13.74% SMA200-34.99% Volume25,382 Change2.33%
Date Action Analyst Rating Change Price Target Change
Jan-06-23Upgrade Piper Sandler Neutral → Overweight $2 → $3
Jan-06-23Upgrade Jefferies Hold → Buy $2.50 → $3
Mar-23-22Downgrade Piper Sandler Overweight → Neutral $15 → $4
Jan-07-22Downgrade JP Morgan Overweight → Neutral $30 → $12
Jan-06-22Downgrade Jefferies Buy → Hold
Sep-09-21Initiated SVB Leerink Outperform $29
May-17-21Resumed Piper Sandler Overweight $47
Nov-10-20Initiated Piper Sandler Overweight $35
Nov-10-20Initiated JP Morgan Overweight $33
Nov-10-20Initiated Jefferies Buy $26
Nov-10-20Initiated Cantor Fitzgerald Overweight $28
Sep-21-23 07:30AM
Aug-03-23 04:05PM
Jul-27-23 04:05PM
Jul-19-23 07:30AM
Jun-21-23 04:30PM
07:30AM Loading…
Jun-07-23 07:30AM
Jun-05-23 06:09AM
May-24-23 05:26PM
May-12-23 05:05PM
May-04-23 07:25PM
Apr-27-23 04:05PM
Apr-17-23 06:51AM
Apr-11-23 06:50PM
Mar-29-23 04:05PM
06:25PM Loading…
Mar-09-23 06:25PM
Feb-28-23 04:05PM
Feb-16-23 08:00AM
Feb-14-23 08:00AM
Feb-10-23 07:00AM
Feb-09-23 11:39AM
Feb-08-23 04:05PM
Jan-23-23 07:53AM
Jan-05-23 08:00AM
Dec-14-22 04:05PM
Dec-08-22 08:00AM
Dec-05-22 05:13AM
Nov-04-22 08:05AM
04:05PM Loading…
Nov-02-22 04:05PM
Oct-21-22 09:05AM
Oct-19-22 04:15PM
Oct-18-22 07:30AM
Oct-14-22 08:00AM
Sep-29-22 08:40AM
Sep-28-22 04:32PM
Aug-16-22 08:00AM
Aug-04-22 04:05PM
Jul-27-22 04:05PM
Jul-25-22 08:00AM
Jun-27-22 12:20PM
Jun-22-22 08:00AM
Jun-06-22 08:00AM
May-23-22 04:05PM
May-04-22 04:05PM
May-03-22 08:00AM
Apr-27-22 04:05PM
Apr-05-22 09:25AM
Apr-04-22 08:00AM
Mar-22-22 11:09AM
Mar-10-22 04:05PM
Mar-02-22 04:05PM
Feb-11-22 07:00AM
Feb-03-22 04:05PM
Jan-26-22 08:00AM
Jan-18-22 04:21AM
Jan-14-22 04:51PM
Jan-12-22 09:31AM
Jan-11-22 09:12AM
Jan-07-22 12:24PM
Jan-06-22 06:21PM
Dec-21-21 04:05PM
Dec-09-21 08:00AM
Dec-07-21 08:00AM
Nov-23-21 07:00AM
Nov-22-21 08:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
Nov-12-21 08:00AM
Nov-09-21 12:00PM
Nov-04-21 04:05PM
Oct-28-21 04:05PM
Oct-20-21 06:02AM
Oct-14-21 04:58PM
Oct-11-21 08:00AM
Sep-20-21 04:05PM
Aug-05-21 04:05PM
Jul-29-21 04:05PM
Jul-06-21 01:37AM
Jun-30-21 10:08PM
Jun-28-21 04:10PM
Jun-21-21 08:00AM
Jun-14-21 08:00AM
Jun-10-21 07:00AM
May-20-21 04:05PM
May-10-21 04:05PM
May-05-21 08:00AM
Apr-27-21 04:01PM
Apr-14-21 08:00AM
Mar-23-21 04:05PM
Mar-10-21 08:00AM
Mar-08-21 08:00AM
Feb-03-21 08:00AM
Jan-16-21 01:06AM
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.